Appili Therapeutics Inc. (APLIF)
| Previous Close | 0.0294 |
| Open | 0.0243 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0243 - 0.0280 |
| 52 Week Range | 0.0160 - 0.0760 |
| Volume | |
| Avg. Volume | 230,367 |
| Market Cap | 3.395M |
| Beta (5Y Monthly) | 1.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Reuters
UPDATE 2-Canada's Appili gets US FDA approval for oral antibiotic solution
The U.S. Food and Drug Administration (FDA) on Monday approved Canadian drugmaker Appili Therapeutics' liquid oral form of antibiotic drug metronidazole, offering an alternative to patients who have difficulty taking injections or pills. An injectable form of the drug, which is commonly used in the treatment of bacterial and parasitic infections, has been in shortage in the United States since early last year due to high demand and regulatory delays. Appili said its partner, privately-held Saptalis, will sell the newly approved form of the drug under the brand name Likmez in the United States.
- Baystreet
Stocks in play: Appili Therapeutics Inc.
Has entered into a definitive agreement with respect to an unsecured $300,000 bridge loan from Bloom ...
- Simply Wall St.
Appili Therapeutics Full Year 2023 Earnings: CA$0.081 loss per share (vs CA$0.38 loss in FY 2022)
Appili Therapeutics ( TSE:APLI ) Full Year 2023 Results Key Financial Results Revenue: CA$334.2k (down 76% from FY...
